| Literature DB >> 35845072 |
Yue Zheng1,2,3,4,5, Bingcai Qi3,4,5,6, Wenqing Gao2,3,4,5,6, Zhenchang Qi3,4,5,6, Yanwu Liu3,4,5,6, Yuchao Wang1,3,4,5,6, Jianyu Feng3,4,5,6, Xian Cheng3,4,5,6, Zhiqiang Luo3,4,5,6, Tong Li1,2,3,4,5,6.
Abstract
Background: The macrophages are involved in all stages of cardiovascular diseases, demonstrating the correlation between inflammation, atherosclerosis, and myocardial infarction (MI). Here, we aim to investigate macrophages-related genes in the deterioration of atherosclerosis.Entities:
Keywords: GO/KEGG pathways analysis; GSEA; PPI; atherosclerosis; differentially expressed genes; immune infiltration; macrophages; progression
Year: 2022 PMID: 35845072 PMCID: PMC9282674 DOI: 10.3389/fcvm.2022.890321
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1Identification of differentially expressed genes (DEGs) in ruptured plaques and stable plaques. (A) Abundance of immune cells estimated by the xCell algorithm in GSE41571. (B) Upset diagram of plasm B cells, fibroblasts, activated myeloid dendritic cells, M0, M1, and M2 Macrophages-related DEGs with Pearson correlation coefficients >0.6. (C,D) Heatmap (C) and Volcano plot (D) of DEGs between ruptured plaques and stable plaques.
Figure 2Enrichment pathway analysis of the DEMRGs. (A) Venn diagram showed 509 differentially expressed genes (DEGs) among M0, M1, and M2 macrophages were regarded as DEMRGs. (B) The significant Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enriched by DEMRGs. (C) The gene sets associated with DEMRGs using Gene Set Enrichment Analysis (GSEA) analysis. DEMRGs, differentially expressed macrophages-related genes.
The significant GO and KEGG pathways enriched by 509 DEGs.
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| BP | GO:0043312 | neutrophil degranulation | 33/438 | 485/18670 | 4.91e-08 | 7.95e-05 | 6.90e-05 |
| BP | GO:0002283 | neutrophil activation involved in immune response | 33/438 | 488/18670 | 5.68e-08 | 7.95e-05 | 6.90e-05 |
| BP | GO:0043062 | extracellular structure organization | 30/438 | 422/18670 | 7.82e-08 | 7.95e-05 | 6.90e-05 |
| BP | GO:0042119 | neutrophil activation | 33/438 | 498/18670 | 9.14e-08 | 7.95e-05 | 6.90e-05 |
| BP | GO:0002446 | neutrophil mediated immunity | 33/438 | 499/18670 | 9.58e-08 | 7.95e-05 | 6.90e-05 |
| CC | GO:0005774 | vacuolar membrane | 38/455 | 412/19717 | 3.97e-13 | 1.83e-10 | 1.52e-10 |
| CC | GO:0005765 | lysosomal membrane | 34/455 | 354/19717 | 2.31e-12 | 3.84e-10 | 3.20e-10 |
| CC | GO:0098852 | lytic vacuole membrane | 34/455 | 355/19717 | 2.50e-12 | 3.84e-10 | 3.20e-10 |
| CC | GO:0062023 | collagen-containing extracellular matrix | 35/455 | 406/19717 | 2.36e-11 | 2.71e-09 | 2.26e-09 |
| CC | GO:0005581 | collagen trimer | 14/455 | 87/19717 | 1.16e-08 | 1.07e-06 | 8.87e-07 |
| MF | GO:0005201 | extracellular matrix structural constituent | 24/441 | 163/17697 | 2.45e-12 | 1.64e-09 | 1.56e-09 |
| MF | GO:0003779 | actin binding | 31/441 | 431/17697 | 1.37e-07 | 4.59e-05 | 4.38e-05 |
| MF | GO:0030020 | extracellular matrix structural constituent conferring tensile strength | 9/441 | 41/17697 | 5.90e-07 | 1.32e-04 | 1.26e-04 |
| MF | GO:0050839 | cell adhesion molecule binding | 30/441 | 499/17697 | 8.67e-06 | 0.001 | 0.001 |
| MF | GO:0023023 | MHC protein complex binding | 6/441 | 25/17697 | 2.74e-05 | 0.004 | 0.003 |
| KEGG | hsa04142 | Lysosome | 18/224 | 128/8076 | 1.21e-08 | 3.31e-06 | 3.04e-06 |
| KEGG | hsa04974 | Protein digestion and absorption | 12/224 | 103/8076 | 2.55e-05 | 0.003 | 0.003 |
| KEGG | hsa04145 | Phagosome | 12/224 | 152/8076 | 0.001 | 0.050 | 0.046 |
| KEGG | hsa05145 | Toxoplasmosis | 10/224 | 112/8076 | 0.001 | 0.050 | 0.046 |
| KEGG | hsa04940 | Type I diabetes mellitus | 6/224 | 43/8076 | 0.001 | 0.050 | 0.046 |
DEGs, Different Expressed Genes; GO, Gene ONTOLOGY; BP, Biological Process; CC, cellular component; MF, Molecular Function; KEGG, Kyoto Encyclopedia of Genes and Genomes.
The gene set enrichment analysis of 509 DEGs.
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| REACTOME_DEVELOPMENTAL_BIOLOGY | 42 | −0.455736963 | −1.810929732 | 0.003215434 | 0.077020202 | 0.054492291 | 96 |
| REACTOME_COLLAGEN_BIOSYNTHESIS_AND_MODIFYING_ENZYMES | 10 | −0.658049427 | −1.851927505 | 0.003968254 | 0.077020202 | 0.054492291 | 94 |
| REACTOME_NERVOUS_SYSTEM_DEVELOPMENT | 29 | −0.516762957 | −1.911346319 | 0.004424779 | 0.077020202 | 0.054492291 | 96 |
| REACTOME_SIGNALING_BY_RECEPTOR_TYROSINE_KINASES | 29 | −0.48960486 | −1.81089692 | 0.009955752 | 0.077020202 | 0.054492291 | 108 |
| REACTOME_VESICLE_MEDIATED_TRANSPORT | 27 | −0.5008811 | −1.816707985 | 0.011261261 | 0.077020202 | 0.054492291 | 95 |
| REACTOME_DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX | 13 | −0.581448267 | −1.771341344 | 0.011363636 | 0.077020202 | 0.054492291 | 105 |
| REACTOME_COLLAGEN_FORMATION | 11 | −0.618867217 | −1.789243746 | 0.011673152 | 0.077020202 | 0.054492291 | 94 |
| REACTOME_ADAPTIVE_IMMUNE_SYSTEM | 38 | −0.446518499 | −1.740047653 | 0.011866235 | 0.077020202 | 0.054492291 | 98 |
| REACTOME_LEISHMANIA_INFECTION | 10 | 0.590600566 | 2.117895264 | 0.012145749 | 0.077020202 | 0.054492291 | 157 |
| PID_INTEGRIN1_PATHWAY | 13 | −0.575607133 | −1.753546738 | 0.012626263 | 0.077020202 | 0.054492291 | 105 |
| NABA_MATRISOME | 47 | −0.406963953 | −1.643327996 | 0.016985138 | 0.094190311 | 0.066640254 | 105 |
| KEGG_CHEMOKINE_SIGNALING_PATHWAY | 12 | −0.568058265 | −1.685702571 | 0.023017903 | 0.108313156 | 0.076632259 | 77 |
| REACTOME_SIGNALING_BY_GPCR | 27 | −0.465333042 | −1.687774311 | 0.023648649 | 0.108313156 | 0.076632259 | 77 |
| REACTOME_TRANSPORT_OF_SMALL_MOLECULES | 25 | −0.467801517 | −1.67862867 | 0.024858757 | 0.108313156 | 0.076632259 | 50 |
| REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS | 11 | −0.57654683 | −1.666888763 | 0.028534371 | 0.110060624 | 0.077868603 | 105 |
| REACTOME_MEMBRANE_TRAFFICKING | 22 | −0.479364201 | −1.661487991 | 0.02886836 | 0.110060624 | 0.077868603 | 95 |
| KEGG_ENDOCYTOSIS | 10 | −0.584690143 | −1.645474815 | 0.035714286 | 0.128151261 | 0.090667846 | 65 |
| REACTOME_INNATE_IMMUNE_SYSTEM | 53 | −0.367172397 | −1.508970204 | 0.04 | 0.135555556 | 0.095906433 | 95 |
| REACTOME_SLC_MEDIATED_TRANSMEMBRANE_TRANSPORT | 10 | 0.458333333 | 1.643584603 | 0.044534413 | 0.137169312 | 0.097048176 | 257 |
| KEGG_ECM_RECEPTOR_INTERACTION | 10 | −0.57270396 | −1.611742482 | 0.044973545 | 0.137169312 | 0.097048176 | 94 |
NES, normalized enrichment score.
Figure 3The hub differentially expressed macrophages-related genes (DEMRGs) and enrichment pathway analysis. (A) The hub DEMRGs were shown using NetworkAnalyst 3.0. (B) The significant GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enriched by the hub DEMRGs. (C) The heatmap of the hub DEMRGs in GSE41571. (D) Left ventricle tissue-specific protein–protein interactions (PPIs) were applied, demonstrating UBC, FN1, PPP1CA, YAP1, and SOCS3 were core regulators in the network.
The significant GO and KEGG pathways enriched by hub DEMRGs.
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| BP | GO:0018108 | Peptidyl-tyrosine phosphorylation | 8/30 | 363/18670 | 7.62e-08 | 5.68e-05 | 3.51e-05 |
| BP | GO:0018212 | Peptidyl-tyrosine modification | 8/30 | 366/18670 | 8.11e-08 | 5.68e-05 | 3.51e-05 |
| BP | GO:0055024 | Regulation of cardiac muscle tissue development | 5/30 | 100/18670 | 5.11e-07 | 2.38e-04 | 1.47e-04 |
| BP | GO:0048738 | Cardiac muscle tissue development | 6/30 | 233/18670 | 1.64e-06 | 5.73e-04 | 3.55e-04 |
| BP | GO:0055025 | Positive regulation of cardiac muscle tissue development | 4/30 | 62/18670 | 2.83e-06 | 6.83e-04 | 4.23e-04 |
| CC | GO:0043197 | Dendritic spine | 4/30 | 169/19717 | 1.20e-04 | 0.008 | 0.006 |
| CC | GO:0044309 | Neuron spine | 4/30 | 171/19717 | 1.26e-04 | 0.008 | 0.006 |
| CC | GO:0098978 | Glutamatergic synapse | 5/30 | 349/19717 | 1.67e-04 | 0.008 | 0.006 |
| CC | GO:0045121 | Membrane raft | 4/30 | 315/19717 | 0.001 | 0.037 | 0.027 |
| CC | GO:0098857 | Membrane microdomain | 4/30 | 316/19717 | 0.001 | 0.037 | 0.027 |
| MF | GO:0004713 | Protein tyrosine kinase activity | 4/30 | 134/17697 | 7.39e-05 | 0.012 | 0.008 |
| MF | GO:0004714 | Transmembrane receptor protein tyrosine kinase activity | 3/30 | 62/17697 | 1.55e-04 | 0.012 | 0.008 |
| MF | GO:0019199 | Transmembrane Receptor Protein Kinase Activity | 3/30 | 79/17697 | 3.19e-04 | 0.015 | 0.010 |
| MF | GO:0042813 | Wnt-activated receptor activity | 2/30 | 17/17697 | 3.72e-04 | 0.015 | 0.010 |
| MF | GO:0051721 | Protein phosphatase 2A binding | 2/30 | 32/17697 | 0.001 | 0.035 | 0.023 |
| KEGG | hsa05205 | Proteoglycans in cancer | 7/28 | 205/8076 | 4.61e-06 | 7.43e-04 | 4.71e-04 |
| KEGG | hsa04728 | Dopaminergic synapse | 5/28 | 132/8076 | 7.86e-05 | 0.005 | 0.003 |
| KEGG | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 5/28 | 143/8076 | 1.15e-04 | 0.005 | 0.003 |
| KEGG | hsa05224 | Breast cancer | 5/28 | 147/8076 | 1.31e-04 | 0.005 | 0.003 |
| KEGG | hsa04151 | PI3K-Akt signaling pathway | 7/28 | 354/8076 | 1.56e-04 | 0.005 | 0.003 |
DEMRGs, Different Expressed Macrophages-related Genes; GO, Gene ONTOLOGY; BP, Biological Process; CC, cellular component; MF, Molecular Function; KEGG, Kyoto Encyclopedia of Genes andGenomes.
Figure 4The hub differentially expressed macrophages-related genes (DEMRGs) and their interactions. (A) The hub DEMRGs-chemical interactions. (B–D) The hub DEMRGs, including FLT1 (B), GNAl1 (C), and HCK (D) and their drug interactions.
Figure 5Expression patterns of the hub differentially expressed macrophages-related genes (DEMRGs) were validated in the GSE163154 dataset. (A,B) The principal components analysis (PCA) diagram (A) and Volcano plot (B) between the patients with intraplaque hemorrhage and non-intraplaque hemorrhage. (C) The expression level of the hub DEMRGs. (D) The receiver operation characteristic (ROC) curves of the hub DEMRGs validated in the patients with intraplaque hemorrhage compared to control. (E) The joint ROC curves of the hub validated DEMRGs. IPH, intraplaque hemorrhage. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.
Figure 6Expression patterns of the hub differentially expressed macrophages-related genes (DEMRGs) were validated in the GSE116250 and GSE135055 datasets. (A) The expression level of the hub DEMRGs in patients with dilated cardiomyopathy compared to control. (B) The receiver operation characteristic (ROC) curves of the validated DEMRGs in patients with dilated cardiomyopathy. (C) The expression level of the hub DEMRGs in patients with ischemic cardiomyopathy compared to control. (D) The ROC curves of the validated DEMRGs in patients with ischemic cardiomyopathy. (E) The expression level of the hub DEMRGs in patients with ischemia-induced heart failure compared to control. (F) The ROC curves of the validated DEMRGs in patients ischemia-induced heart failure. DCM, dilated cardiomyopathy; ICM, ischemic cardiomyopathy; HF, heart failure. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.
The hub genes validated in GEO datasets.
|
|
|
|---|---|
| Only ICM | SOCS3 |
| Only HF | MRPS21 |
| Only IPH | NAPA |
| ICM AND DCM NOT HF NOT IPH | HES1 |
| ICM AND HF NOT DCM NOT IPH | STRN |
| ICM AND IPH NOT DCM NOT HF | HCK |
| ICM AND DCM AND HF NOT IPH | FN1 |
| ICM AND DCM AND IPH NOT HF | GNB2 |
| DCM AND HF AND IPH NOT ICM | MYH10 |
| ICM AND DCM AND HF AND IPH | NET1 |
The hub genes validated in ICM and IPH GEO datasets were labeled blue.
Figure 7The protein expression level of the nine screened hub differentially expressed macrophages-related genes (DEMRGs) in atherosclerosis and myocardial infarction (MI) mice model. (A) The expression level of the nine hub DEMRGs in atherosclerosis. (B) The expression level of the nine hub DEMRGs in MI and SHAM groups in ApoE-/- and C57Bl/6J mice. (C–J) The correlation between left ventricular ejection fraction (LVEF) and the nine DEMRGs expression level in the MI mice model, including SYNJ2 (C), NET1 (D), FZD7 (E), LCP2 (F), EIF4EBP1 (G), HCK (H), GNB2 (I), and PPP4C (J). *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.